CA2634693A1 - Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition - Google Patents

Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition Download PDF

Info

Publication number
CA2634693A1
CA2634693A1 CA002634693A CA2634693A CA2634693A1 CA 2634693 A1 CA2634693 A1 CA 2634693A1 CA 002634693 A CA002634693 A CA 002634693A CA 2634693 A CA2634693 A CA 2634693A CA 2634693 A1 CA2634693 A1 CA 2634693A1
Authority
CA
Canada
Prior art keywords
oligosaccharides
composition
lipid
total
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002634693A
Other languages
English (en)
French (fr)
Inventor
Renate Maria Louise Zwijsen
Guenther Boehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2634693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20050077972 external-priority patent/EP1800675B1/en
Priority claimed from PCT/NL2006/050274 external-priority patent/WO2008054192A1/en
Application filed by Individual filed Critical Individual
Publication of CA2634693A1 publication Critical patent/CA2634693A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pediatric Medicine (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
CA002634693A 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition Abandoned CA2634693A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05077972.7 2005-12-23
EP20050077972 EP1800675B1 (en) 2005-12-23 2005-12-23 Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
PCT/NL2006/050274 WO2008054192A1 (en) 2006-11-02 2006-11-02 Use of nutritional compositions for preventing disorders
NLPCT/NL2006/050274 2006-11-02
PCT/NL2006/050331 WO2007073194A2 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition

Publications (1)

Publication Number Publication Date
CA2634693A1 true CA2634693A1 (en) 2007-06-28

Family

ID=37964343

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002634895A Abandoned CA2634895A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
CA002634693A Abandoned CA2634693A1 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
CA002634117A Abandoned CA2634117A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002634895A Abandoned CA2634895A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002634117A Abandoned CA2634117A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity

Country Status (14)

Country Link
US (4) US20090186803A1 (enExample)
EP (4) EP1962617A2 (enExample)
JP (1) JP2009521214A (enExample)
CN (1) CN103054048B (enExample)
AU (3) AU2006327995B2 (enExample)
BR (3) BRPI0620465A2 (enExample)
CA (3) CA2634895A1 (enExample)
ES (1) ES2537080T3 (enExample)
HU (1) HUE026440T2 (enExample)
MY (2) MY149164A (enExample)
PL (1) PL1962823T3 (enExample)
PT (1) PT1962823E (enExample)
RU (3) RU2444210C2 (enExample)
WO (3) WO2007073193A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
CL2008002650A1 (es) * 2007-09-07 2010-07-23 Nestec Sa Rango de productos alimenticios para infantes donde cada producto incluye menos de 10% de energia total del producto proporcionado por el azucar incorporado; regimen alimenticio para alcanzar las necesidades nutraicionales del infante durante diferentes etapas de desarrollo al administrar un rango de productos; usos.
MX2010002978A (es) * 2007-09-17 2010-06-09 Nutricia Nv Formulacion nutritiva con alto contenido energetico.
RU2611808C2 (ru) * 2007-11-01 2017-03-01 Энзимотек Лтд. Липидная смесь для детского питания
ES2611203T3 (es) * 2007-12-21 2017-05-05 N.V. Nutricia Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal
US20100310725A1 (en) * 2007-12-31 2010-12-09 Kathleen Reidy Nutritionally appropriate menu of food products for children
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
SI2296494T2 (sl) * 2008-06-16 2022-08-31 N.V. Nutricia Mlečna formulacija z maščobnim gradientom za dojenčka
US9491955B2 (en) 2008-08-25 2016-11-15 Brandeis University Balanced myristate- and laurate-containing edible oil
SI2346355T1 (sl) 2008-09-02 2020-03-31 N.V. Nutricia Prehranski sestavki z lipidnimi globulami z velikim premerom z oblogo, ki obsega polarne lipide
NZ571856A (en) * 2008-10-09 2011-02-25 Fonterra Corporate Res And Dev Ltd Use of a phospholipid and ganglioside composition for the treatment or prevention of gout
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
MX2011004921A (es) 2008-12-08 2011-05-30 Nestec Sa Modulacion de la grasa corporal infantil.
WO2010068086A1 (en) * 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
RU2540538C2 (ru) * 2009-01-19 2015-02-10 Нестек С.А. Питательная композиция для младенцев
WO2010106384A1 (fr) * 2009-03-16 2010-09-23 Societe La Biochimie Appliquee (Solabia) Compositions nutraceutiques, pharmaceutiques ou alimentaires a base de gluco-oligosaccharides
SG173914A1 (en) * 2009-04-01 2011-10-28 Nestec Sa Reduction of risk of obesity
WO2010119088A2 (en) * 2009-04-15 2010-10-21 Bodo Melnik Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity
WO2011071367A1 (en) 2009-12-11 2011-06-16 N.V. Nutricia Metabolic imprinting effects of structured lipids
PL2353595T3 (pl) 2010-01-19 2016-03-31 Mjn Us Holdings Llc Kompensacja żywieniowa w diecie typu zachodniego
JP5581071B2 (ja) 2010-02-03 2014-08-27 花王株式会社 ミトコンドリア機能向上剤
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
EP2452572A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
CA2827555A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
JP2014506891A (ja) * 2011-02-16 2014-03-20 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ
EP2675444A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
CA2827579A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
EP2514435A1 (en) * 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases
WO2012173467A1 (en) 2011-06-16 2012-12-20 N.V. Nutricia Metabolic imprinting effects of specifically designed lipid component
WO2013036102A1 (en) * 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with cholesterol
WO2013036103A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with large lipid globules
WO2013057061A1 (en) * 2011-10-18 2013-04-25 Nestec S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
EP2583562A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for infants at risk of obesity or diabetes
EP3804700A1 (en) * 2012-02-17 2021-04-14 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
SE536599C3 (sv) 2012-04-10 2017-01-10 Hero Ag Näringssammansättning med lågt kalori- och lågt proteininnehåll
WO2013191533A1 (en) * 2012-06-18 2013-12-27 N.V. Nutricia Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
WO2014058301A1 (en) * 2012-10-12 2014-04-17 N.V. Nutricia Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
CN105120688A (zh) * 2013-04-10 2015-12-02 雀巢产品技术援助有限公司 具有特定比率的低含量MCFAs和相对高含量不饱和脂肪酸的婴儿配方乳，及其在促进婴儿认知功能的健康建立方面的用途
MX2015011979A (es) * 2013-04-10 2015-12-09 Nestec Sa Formula infantil con un bajo contenido de acidos grasos de cadena mediaen proporciones especificas, y su uso para promover y/o asegurar un crecimiento balanceado en los lactantes.
SE537951C2 (sv) * 2013-07-01 2015-12-01 Hero Ag Profylaktisk användning av modersmjölksersättning mot otit
TR201816481T4 (tr) 2013-11-01 2018-11-21 Nutricia Nv Yakalama büyümesi sırasında vücut bileşimini geliştirmek için lipit bileşimler.
CN105744845A (zh) * 2013-11-29 2016-07-06 雀巢产品技术援助有限公司 具有磷脂的营养组合物
CN118020922A (zh) * 2013-11-29 2024-05-14 雀巢产品有限公司 按年龄定制的具有不同蛋白质含量的营养组合物
US20160300035A1 (en) * 2013-11-29 2016-10-13 Nestec S.A. Devices, systems and methods of assessing the risk of obesity later in life of an infant or a young child
EP3079497B1 (en) 2013-12-12 2019-10-23 Société des Produits Nestlé S.A. Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function
AU2014361230B2 (en) * 2013-12-12 2018-09-06 Société des Produits Nestlé S.A. Synthetic milk compositions for infants less than three months old and for infants and children more than three months for ensuring optimal growth and preventing obesity
WO2015086170A1 (en) 2013-12-12 2015-06-18 Nestec S.A. Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children
EP3079499B1 (en) * 2013-12-12 2019-02-20 Nestec S.A. Synthetic milk compositions comprising polyunsaturated fatty acids (pufas) for promoting the healthy establishment of cognitive function in male and female infant and children
JP6336750B2 (ja) * 2013-12-19 2018-06-06 雪印メグミルク株式会社 脂肪蓄積抑制剤
WO2016050754A1 (en) * 2014-09-30 2016-04-07 Nestec S.A. Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses.
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US20180228819A1 (en) * 2015-04-21 2018-08-16 Enzymotec Ltd. Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation
JP6613661B2 (ja) * 2015-07-08 2019-12-04 花王株式会社 食品に対する内臓脂肪のつきにくさの評価方法
RU2731641C2 (ru) 2015-10-15 2020-09-07 Н.В. Нютрисиа Детская смесь cо специальной структурой липида для стимулирования здорового роста
CN108697142A (zh) * 2016-01-26 2018-10-23 雀巢产品技术援助有限公司 用于控制婴儿或幼儿的食物摄入量和生长的包含2FL和LNnT的组合物
AU2017251143B2 (en) 2016-04-11 2021-05-20 Société des Produits Nestlé S.A. Infant nutrition delivering metabolic benefits
BR112018071493A2 (pt) * 2016-04-18 2019-02-19 N.V. Nutricia usos de ácido linoleico (la) e ácido alfa-linolênico (ala) na fabricação de uma composição nutricional, composição nutricional, método para prevenir declínio no funcionamento cognitivo induzido e método para prevenir redução na neurogênese induzida por estresse precoce
WO2017183956A1 (en) * 2016-04-18 2017-10-26 N.V. Nutricia Linoleic acid and alpha-linolenic acid for use for reducing early-life stress induced cognitive decline
EP3471562A4 (en) * 2016-06-15 2020-07-29 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders
WO2018104512A1 (en) 2016-12-09 2018-06-14 N.V. Nutricia Nutritional composition for improving cell membranes
BR112019028007A2 (pt) 2017-06-30 2020-07-07 N.V. Nutricia composição nutricional, uso de uma combinação de bifidobacterium breve e oligossacarídeos não digeríveis, e método para prevenir e/ou reduzir o risco de ocorrência de doença hepática gordurosa
EP4159224A1 (en) 2017-06-30 2023-04-05 N.V. Nutricia Synbiotic composition for preventing chronic inflammation
CN111526729A (zh) * 2018-02-23 2020-08-11 弗门尼舍有限公司 贮存稳定的粉末状组合物
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
US12005083B1 (en) 2019-06-24 2024-06-11 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
CN114554873A (zh) * 2019-10-29 2022-05-27 Aak股份有限公司 包含乳磷脂和蛋磷脂的营养组合物
CN114052243A (zh) * 2020-07-29 2022-02-18 江苏伯克投资管理有限公司 山羊乳提取物的制备及其在全营养特殊医学用途配方食品中的应用
CN112972488B (zh) * 2021-03-02 2022-12-23 青岛农业大学 一种具有抗高尿酸血症活性的岩藻寡糖及其制备方法和应用
MX2024004182A (es) * 2021-10-13 2024-04-23 Nestle Sa Composicion nutricional para mejorar el sue?o.
WO2023208925A1 (en) 2022-04-25 2023-11-02 N.V. Nutricia Nutritional composition for use in preventing programmed obesity in female infants

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59187787A (ja) * 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法スフインゴリン脂質誘導体の製法
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
US5366914A (en) * 1992-01-29 1994-11-22 Nec Corporation Vertical power MOSFET structure having reduced cell area
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US6194009B1 (en) * 1996-11-22 2001-02-27 Princeton Nutrition, Llc Refrigeration-shelf-stable ultra-pasteurized or pasteurized infant formula
SK112399A3 (en) * 1997-02-21 2000-12-11 Abbott Lab Methods and compositions for reducing the incidence of necrotizing enterocolitis
JPH10262607A (ja) * 1997-03-28 1998-10-06 Snow Brand Milk Prod Co Ltd 乳幼児用栄養組成物
US6413557B1 (en) * 1997-07-02 2002-07-02 Kyung Ja Lee Soy-containing nutrition supplement and process
EP0893064B1 (fr) * 1997-07-22 2003-01-15 Societe Des Produits Nestle S.A. Composition lipidique pour formule infantile et procédé de préparation
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US6579551B1 (en) * 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
DE69904257T2 (de) * 1999-01-20 2003-04-17 N.V. Nutricia, Zoetermeer Säuglingsnährpräparat
RU2275041C2 (ru) * 1999-04-29 2006-04-27 Сосьете Де Продюи Нестле С.А. Состав молочной смеси, способ его получения и молочная смесь, содержащая его (варианты)
JP3544493B2 (ja) * 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
US6465714B2 (en) * 1999-11-05 2002-10-15 Arexis Ab Congenic animal models of non-insulin dependent diabetes mellitus
WO2002051264A2 (en) * 2000-12-27 2002-07-04 N.V. Nutricia Nutritional composition with health promoting action containing oligo-saccharides
US7090862B2 (en) * 2001-03-30 2006-08-15 Abbott Laboratories Method of improving the antioxidant status of an infant
WO2003005836A2 (en) 2001-07-10 2003-01-23 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
IL150240A (en) * 2002-06-16 2005-07-25 Lipogen Ltd Infant formula supplemented with phospholipids
AU2003251557A1 (en) * 2002-06-28 2004-01-19 Richard C. Theuer Fat compositions for infant formula and methods therefor
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
US20050175759A1 (en) * 2004-02-09 2005-08-11 Atul Singhal Newborn infant formulas and feeding methods
US6753350B1 (en) * 2003-03-24 2004-06-22 Bristol-Myers Squibb Company Method to reduce the incidence of intraventricular hemorrhage in preterm infants
US6998392B2 (en) * 2003-04-02 2006-02-14 Mti Meta Tech Inc. Formulation to treat or prevent parasitic infection
ATE433674T1 (de) * 2003-06-23 2009-07-15 Nestec Sa Säuglingsnährpräparat oder folgemilch
EP1643862A1 (en) * 2003-06-24 2006-04-12 University of Kansas Medical Center Infant formula
IL158554A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
WO2005063050A1 (en) 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
EP1566439A1 (en) 2004-02-20 2005-08-24 Nestec S.A. Preventing or treating obesity
BRPI0513500C8 (pt) * 2004-07-19 2022-06-14 Robert Johan Jozeph Hageman Uso de equivalentes de aspartato e composição nutricional ou farmacêutica
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
CN101242748A (zh) * 2004-11-26 2008-08-13 荷兰纽迪希亚公司 含有蛋白酶抑制剂的婴儿营养品
CA2593033A1 (en) 2004-12-27 2006-07-06 Nestec S.A. Use of infant formula with reduced protein content
TR201820329T4 (tr) * 2005-02-28 2019-01-21 Nutricia Nv Probiyotik İçeren Besin Bileşimi
DE602006006654D1 (de) * 2005-03-08 2009-06-18 Nestec Sa Verfahren zur herstellung von nährmittelzusammensetzungen
US20070191264A1 (en) * 2005-05-05 2007-08-16 Bristol-Myers Squibb Company, A Delaware Corporation Methods for inhibiting the growth of bacteria

Also Published As

Publication number Publication date
US20160175393A1 (en) 2016-06-23
AU2006327996B2 (en) 2012-03-29
MY162091A (en) 2017-05-31
WO2007073193A3 (en) 2007-08-16
US20110136732A1 (en) 2011-06-09
EP1962823A2 (en) 2008-09-03
RU2417712C2 (ru) 2011-05-10
WO2007073193A2 (en) 2007-06-28
BRPI0620465A2 (pt) 2011-11-16
AU2006327997A1 (en) 2007-06-28
RU2444210C2 (ru) 2012-03-10
AU2006327996A1 (en) 2007-06-28
EP1973424A2 (en) 2008-10-01
AU2006327997A8 (en) 2008-07-31
WO2007073194A3 (en) 2008-06-12
CA2634117A1 (en) 2007-06-28
RU2008130370A (ru) 2010-01-27
WO2007073194A2 (en) 2007-06-28
RU2008130365A (ru) 2010-01-27
ES2537080T3 (es) 2015-06-02
US20120121757A1 (en) 2012-05-17
CN103054048B (zh) 2014-11-19
CA2634895A1 (en) 2007-06-28
AU2006327995B2 (en) 2012-09-13
AU2006327995A1 (en) 2007-06-28
US20090186803A1 (en) 2009-07-23
MY149164A (en) 2013-07-31
JP2009521214A (ja) 2009-06-04
RU2414905C2 (ru) 2011-03-27
WO2007073192A3 (en) 2007-08-16
PT1962823E (pt) 2015-06-29
EP1962823B1 (en) 2015-03-04
EP1962617A2 (en) 2008-09-03
EP2305049A1 (en) 2011-04-06
HUE026440T2 (en) 2016-06-28
WO2007073192A2 (en) 2007-06-28
BRPI0620451A2 (pt) 2011-04-12
AU2006327997B2 (en) 2012-03-29
BRPI0620466A2 (pt) 2011-11-16
US8871218B2 (en) 2014-10-28
PL1962823T3 (pl) 2015-08-31
RU2008130367A (ru) 2010-01-27
CN103054048A (zh) 2013-04-24
EP1973424B1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
AU2006327997B2 (en) Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
USRE45483E1 (en) Infant nutritional compositions for preventing obesity
EP2861087B1 (en) Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
EP2542101B1 (en) Modulation of post-prandial fat absorption
NZ569264A (en) Infant nutritional compositions for preventing obesity comprising linoleic acid
WO2013036104A1 (en) Infant nutrition for regulating food intake later in life
US20170151175A1 (en) Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140521